The company will issue 23.81 million shares at A$0.105 per share. Participants in the placement include OppenheimerFunds and other US and Australian investors.
Proceeds are being allocated to maintain development timelines for the company’s two lead diagnostic programs – a rapid point-of-care test for tuberculosis and an on-site test for determining wheat quality and thus pricing.